SCHEMBL3013029

SCHEMBL3013029

CCCc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(OC)cc4)CC3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.61
ALDH1A1 P00352 5/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MAPT P10636 6/20 0.60
USP2 O75604 2/20 0.60
RECQL P46063 1/20 0.60
HSD17B10 Q99714 1/20 0.60
POLB P06746 3/20 0.59
KCNQ1 P51787 1/20 0.56
RAB9A P51151 4/20 0.54
NPC1 O15118 2/20 0.54
LMNA P02545 5/20 0.53
MAPK1 P28482 5/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
TP53 P04637 2/20 0.50
HTT P42858 2/20 0.50
MMP1 P03956 1/20 0.50
MMP3 P08254 1/20 0.50
MMP7 P09237 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014486 0.92 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3008450 0.91 ALDH1A1 (0.73) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3014052 0.89 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3005136 0.89 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3010437 0.89 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3012838 0.88 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3017071 0.88 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3018521 0.88 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3002766 0.88 SMN1; SMN2 (0.80) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3010651 0.88 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.